Type I diabetes mellitus (T1DM) increases atherosclerotic cardiovascular disease, while the underlying pathophysiology is still incompletely understood. We investigated whether experimental T1DM impacts HDL-mediated reverse cholesterol transport (RCT).
Introduction
Atherosclerotic cardiovascular disease (CVD) is a predominant cause of morbidity and mortality in type 1 diabetes mellitus (T1DM) patients (1, 2) . Compared with subjects without diabetes, T1DM confers a 7-fold increase in the risk of fatal CVD (2) . However, the mechanisms underlying accelerated atherosclerosis in T1DM are still incompletely understood.
Plasma high density lipoprotein (HDL) cholesterol levels are inversely related to the incidence of CVD (3, 4) . The role of this lipoprotein in promoting reverse cholesterol transport (RCT) is currently regarded the main established atheroprotective property of HDL (5, 6) . The critical steps in RCT comprise initial efflux of excess cholesterol from lipid-laden macrophages within atherosclerotic lesions towards HDL for transport through the plasma compartment, followed by the subsequent uptake of cholesterol into the liver for excretion into bile and feces (7, 8) .
Although T1DM has been associated with changes in sterol metabolism (9) (10) (11) (12) (13) , no data are currently available addressing the impact of T1DM on RCT. Therefore, this study explored the pathophysiological consequences of experimental T1DM on overall RCT as well as the individual steps involved in this process. Our data demonstrate that macrophage-specific RCT is decreased in T1DM despite increased biliary sterol secretion as well as increased fecal excretion of bile acids. Mechanistically, we identified decreased hepatic selective uptake of cholesterol from glycated HDL as a major underlying factor for reduced RCT in T1DM.
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Materials and Methods
Animals
C57BL/6J mice were obtained from Charles River (Sulzfeld, Germany). The animals were caged in animal rooms with alternating 12-hour periods of light (from 7.00 a.m. to 7.00 p.m.) and dark (from 7.00 p.m. to 7.00 a.m.), with ad libitum access to water and mouse chow diet (Arie Blok, Woerden, The Netherlands). Animal experiments were performed in conformity with PHS policy and in accordance with the national laws. All protocols were approved by the responsible ethics committee of the University of Groningen.
Induction of type 1 diabetes mellitus
To induce experimental T1DM, wild-type C57BL/6J were injected intravenously with a single dose of alloxan (65 mg/kg body weight, Sigma, St. Louis, MO, USA), while control mice received an equivalent volume of phosphate-buffered saline (PBS). Blood glucose levels were assessed by tail bleeding using a Onetouch Ultra glucosemeter (LifeScan Benelux, Beerse, Belgium). Plasma insulin levels were determined using an ultrasensitive mouse insulin ELISA kit (Alpco Diagnostics, Salem NH, USA). plasma samples from mice of the same experimental group were subjected to fast protein liquid chromatography (FPLC) gel filtration using a Superose 6 column (GE Healthcare, Uppsala, Sweden) as described (14) . Samples were chromatographed at a flow rate of 0.5 mL/min, and fractions of 500 µl each were collected. Individual fractions were assayed for cholesterol concentrations as described above. Plasma plant sterol levels were measured by gas chromatography exactly as previously published (15) .
Analysis of liver lipid composition
To determine hepatic cholesterol, phospholipid, and triglyceride content, liver tissue was homogenized, and lipids were extracted following the general procedure of Bligh and Dyer as described (16) . Triglycerides and cholesterol were measured using commercial kits as detailed above. Phospholipid content of the liver was determined essentially as published previously (16) .
Bile collection and assessment of biliary excretion of cholesterol, phospholipids, and bile acids
Continuous bile cannulation was performed on day 10 after injection with either alloxan or PBS. Bile was collected during 30 minutes under Hypnorm (fentanyl/fluanisone; 1 ml/kg) and diazepam (10 mg/kg) anesthesia using a humidified
Fecal bile acid and neutral sterol analysis
Feces of individually housed mice were collected over a period of 24 h, starting on day 8. Fecal samples were dried, weighed, and thoroughly ground. Aliquots were used for determination of bile acids and neutral sterols by gas liquid chromatography as described (17).
In vivo reverse cholesterol transport study
In vivo macrophage-to-feces RCT studies were performed from day 9-11 after either alloxan or saline injection following a previously described protocol (18). Briefly, wild-type C57BL/6J donor mice were injected intraperitoneally with 1.0 ml of 4% Brewer thioglycollate medium (Becton Dickinson, Le Point de Claix, France). On day 4 after thioglycollate injection, peritoneal macrophages were harvested as described (19).
Macrophages were plated in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA) and penicillin (100 U/ml)/streptomycin (100 µg/ml) (Invitrogen) and were allowed to adhere for 4 h at 37 °C under 5% CO 2 humidified air. Then non-adherent cells were removed by washing twice with PBS followed by loading of the macrophages with 50 µg/ml acetylated low density lipoprotein (LDL) and 3 µCi/ml Aliquots were separated into bile acid and neutral sterol fractions as previously published (17). Briefly, samples were first heated for 2 h at 80 °C in alkaline methanol and then extracted three times with petroleum ether. In the top layer, counts within the neutral sterol fraction were determined by liquid scintillation counting, while counts incorporated into bile acids were assessed from the bottom layer. Counts recovered from the respective aliquots were related to the total amount of feces produced over the whole experimental period. All obtained counts were expressed relative to the administered tracer dose.
Determination of fractional intestinal cholesterol absorption
Fractional cholesterol absorption was determined using a dual isotope method essentially as described (21 and an oral dose of 0.6 mg cholesterol-D 5 dissolved in medium-chain triglyceride oil.
Blood spots were collected from the tail on filter paper at t = 0, 3, 6, 12, 24, 48 and 72 h. Labeled HDL preparations were then added to the cells in serum-free DMEM, and incubations were continued for 6 h. Supernatants and cells were processed as detailed above for macrophages, and radioactivity within medium and cells was determined.
Cellular uptake is expressed as the percentage of counts recovered from the cells in relation to the counts present on the plate (sum of medium and cells).
Determination of HDL glycation
The extent of HDL glycation was determined using an enzymatic fructosamine assay (Diazyme, Dresden, Germany) according to the manufacturer's protocol. Mouse by guest, on November 9, 2017 www.jlr.org
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HDL was isolated by ultracentrifugation as described above, and 40 µg of total protein from respective HDL preparations was used in the assay.
In vivo HDL kinetics studies
HDL kinetics studies were performed essentially as published previously (16, 
Western blotting
Western blots for SR-BI were carried out on total liver homogenates as well as on hepatic membrane fractions prepared essentially as described (16) . Protein concentrations were determined with the bicinchoninic acid (BCA) assay (Pierce Biotechnology, Inc., Rockford, IL, USA). Equal amounts of protein were separated by SDS-PAGE electrophoresis and blotted onto nitrocellulose. SR-BI was visualized using a commercially available goat anti-mouse SR-BI antibody (Novus Biologicals, Littleton, CO, USA), followed by the appropriate HRP-conjugated secondary antibody. HRP was detected using chemiluminescence (ECL, GE Healthcare). Quantitation was carried out using the freely available ImageJ software (http://rsb.info.nih.gov/ij/), adjusting the background for the area size of each band and subtracting it from the respective bands.
Results were normalized for the average of the control mice.
Analysis of gene expression by real-time quantitative PCR
Total RNA from mouse livers was isolated using Trizol (Invitrogen) and quantified with a NanoDrop ND-100 UV-Vis spectrophotometer (NanoDrop 
Statistical analysis
Statistical analysis was carried out using the Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL, USA). Values are expressed as means ± SEM. Unpaired Student's t test was used to assess statistical differences between groups.
Statistical significance for all comparisons was assigned at P<0.05.
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Results
Plasma cholesterol levels and liver cholesterol content are increased in type 1 diabetic mice.
Mice treated with alloxan became severely hyperglycemic within 2 days after injection and remained diabetic throughout the 11 days of the experiment (P<0.001, Table 1 ). Consistent with these results, blood HbA1c levels were significantly increased in alloxan-injected mice on day 10 (P<0.001, Table 1 ). The striking decrease in plasma insulin levels (P<0.001, Table 1 ) confirmed alloxan-induced destruction of pancreatic beta cells.
Plasma total cholesterol was increased in diabetic mice (P=0.01, Table 1 ). FPLC profiles showed an overall increase in HDL cholesterol levels and also the appearance of larger HDL particles in the diabetic group ( Figure 1 ). Plasma triglycerides were higher in diabetic mice compared to controls (P<0.01, Table 1 ), while phospholipid and free fatty acid levels remained unchanged (Table 1) .
Body weight in diabetic mice was lower than in controls (P<0.001, Table 1 ).
Although absolute liver weight was not different between the groups, liver weight relative to body weight was increased in T1DM mice (P<0.001, Table 1 ). Hepatic cholesterol content was 22% higher in the diabetic group (P<0.001, Table 1 ), while liver triglycerides and phospholipids were not affected (Table 1) .
Biliary cholesterol and bile acid secretion are increased in type I diabetic mice. 
Hepatic gene expression analysis indicates increased bile acid synthesis in type I diabetic mice.
The hepatic expression of the major transporters for biliary cholesterol, ATPbinding cassette transporter G5 (Abcg5) and Abcg8 was increased by 34% (P<0.05) and 33% (P<0.01), respectively ( Table 2 ). The expression of the biliary phospholipid transporter Abcb4 (Mdr2) was increased by 19% (P<0.05), whereas the expression of the bile acid transporter Abcb11 (Bsep) was not different ( However, a 9-fold (P<0.01) increase in the expression of Cyp7a1 and a 1.7-fold elevated expression of Cyp8b1 (P<0.05) indicated increased bile acid synthesis in diabetic mice.
Macrophage-to-feces RCT is decreased in type I diabetic mice.
Biliary sterol secretion, either as free cholesterol or after metabolic conversion to bile acids, is a critical step in RCT (7). Therefore, a macrophage-to-feces RCT experiment was performed to investigate whether increased biliary sterol secretion in diabetic mice would translate into increased RCT. Following i.p. injection with Figure 4A ). The amount of label present within the liver at time of sacrifice did not differ between the groups ( Figure 4B) . Surprisingly, despite the increased mass biliary sterol secretion, overall macrophage-to-feces RCT was reduced by 20% in diabetic mice compared to controls (9.23 ± 0.79 vs 11.54 ± 0.61 % of injected dose, P<0.05, Figure 4C ). This difference was mainly due to a decreased amount of label excreted within the fecal bile acid fraction of T1DM mice (7.08 ± 0.77 vs 9.11 ± 0.46 % of injected dose, P<0.05, Figure 4C ), while label recovered within the fecal neutral sterol fraction was not different between groups ( Figure 4C ).
The efflux capacity of HDL is not affected in type 1 diabetic mice.
Glycation of apolipoprotein (apo) A-I has been associated with reduced functionality in cholesterol efflux assays (23) . Thus, we first determined whether alloxaninduced T1DM results in increased glycation of HDL proteins. HDL from diabetic mice was more glycated compared to control HDL as judged by a significant increase in fructosamine residues (83 ± 3 vs. 50 ± 6 nmol/mg protein, P<0.01, Figure 5A ). Next, we 
Uptake of HDL cholesterol by the liver is impaired in type I diabetic mice.
Hepatic uptake of HDL cholesterol is another key process in RCT and impaired uptake of HDL cholesterol by the liver would offer an alternative explanation for decreased macrophage-to-feces RCT in diabetic mice. Therefore, the hepatic expression of the selective uptake transporter for HDL cholesterol, scavenger receptor class BI (SR-BI), was investigated. While the mRNA expression of SR-BI was 22% higher in diabetic mice compared to controls (P<0.05, Figure 6A ), neither total nor membrane-associated SR-BI protein expression was different between groups ( Figure 6B ). Besides the expression of SR-BI, a reduced affinity of the ligand, namely the HDL particle, could also impair hepatic selective uptake of HDL cholesterol. Selective uptake from T1DM Figure 6C ).
To investigate whether reduced hepatic selective uptake als occurs in vivo in T1DM mice a series of HDL kinetic studies was performed. While the HDL protein turnover did not differ between controls mice and T1DM (0.098 ± 0.009 vs 0.089 ± 0.006 pools/h, n.s., Figure 6D ), the HDL-CE FCR was significantly lower in diabetic animals (0.169 ± 0.005 vs 0.131 ± 0.006 pools/h, P<0.01, Figure 6D ) indicating reduced whole body selective uptake. Hepatic uptake of HDL proteins was similar in controls and T1DM mice (26.4 ± 2.6 vs 23.8 ± 2.3 %, n.s., Figure 6E ), however, uptake of HDL-CE was lower in T1DM than controls (46.0 ± 2.4 vs 36.6 ± 2.3 %, P<0.05, Figure 6E) translating into a significant reduction of hepatic selective uptake under diabetic conditions (19.6 ± 1.9 vs 12.8 ± 0.9 %, P<0.05, Figure 6E) . These combined data demonstrate that impaired hepatic selective uptake of cholesterol from T1DM HDL particles occurs also in vivo and indicate that this mechanism contributes to reduced in vivo RCT in T1DM mice.
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Discussion
Our data demonstrate that experimental T1DM results in a decrease in macrophage-to-feces RCT despite increased biliary sterol secretion rates. To delineate the underlying mechanism of this finding our study explored the impact of T1DM on key steps relevant for RCT. While cholesterol efflux towards glycated HDL was not impaired, the functionality of glycated HDL in SR-BI-mediated selective uptake was significantly decreased, conceivably representing a major contributing factor to reduced RCT in T1DM mice. However, our data demonstrate that in the context of a whole HDL particle in vitro cholesterol efflux towards HDL from T1DM mice was unchanged compared with control HDL. This observation is supported by previous studies using isolated total HDL (26, 27) . Combined, these data suggest that glycation of HDL proteins might inhibit ABCA1-mediated efflux, whereas ABCG1-mediated efflux is not affected. Biliary sterol secretion is thought to be a major determinant for the completion of the RCT pathway (7, 8) . Our data show enhanced biliary secretion of bile acids as well as cholesterol in T1DM mice. These results are consistent with previously published data demonstrating that alloxan-or streptozotocin-induced diabetes increased biliary sterol secretion rates in rats (13, 28) . In addition, concentrations of bile acids and cholesterol in gallbladder bile were increased in T1DM mice injected with alloxan as well as in nonobese diabetic (NOD)-mice (11, 29) . Since biliary bile acid secretion is a major driving force for biliary cholesterol secretion (30), the primary point of dysregulation in T1DM is likely in the metabolism of bile acids. Hepatic gene expression analysis indicated increased de novo bile acid synthesis in T1DM animals, for which cholesterol serves as the substrate (31). In contrast to fecal bile acid excretion, fecal neutral sterol excretion was similar between groups despite the 5.5-fold higher biliary cholesterol secretion in the diabetic mice. These data are conceivably explained by 2.1-fold increased cholesterol absorption rates observed in the T1DM mice in our study. In addition, also food intake was almost 2-fold higher in T1DM mice (data not shown), overall resulting in a substantial increase in cholesterol supply from diet. Increased intestinal cholesterol absorption has previously been observed by others in insulin-deficient diabetic rodent models as well as in humans (9, 10, 12, 32) . However, it is important to point out that our study specifically identified decreased SR-BI-mediated selective uptake, which represents the point of entry for macrophage-derived cholesterol into the entero-hepatic system, as the major block in RCT affected in T1DM.
Certain methodological issues have to be considered in the interpretation of our results. HDL kinetic studies using trap labels for HDL proteins as well as HDL cholesteryl ester clearly demonstrated reduced hepatic selective uptake rates in vivo in Increasing evidence suggests that also these atheroprotective functions of HDL particles are impaired in T1DM. The anti-oxidative properties of HDL appear to be diminished in T1DM (37, 38) and the ability of HDL from T1DM patients to counteract the inhibitory effects of oxidized LDL on endothelium-dependent vasorelaxation is also reduced (39) .
In addition, glycation of apoA-I was recently shown to decrease the potency of HDL to inhibit neutrophil infiltration and adhesion molecule expression using the carotid artery collar model in rabbits (40) . In addition to decreased RCT, these alterations are expected to contribute to an overall reduced capacity of diabetic HDL to protect against atherosclerotic CVD. Figure 7 summarizes our current working model on the effects of T1DM on sterol metabolism and RCT. Biliary secretion of bile acids and cholesterol is significantly increased, while hepatic cholesterol synthesis remains largely unaffected. Nevertheless, hepatic cholesterol levels do not decrease, since the liver cholesterol pool in diabetic mice receives more input via increased food intake and higher intestinal cholesterol absorption.
These events result in an enhanced cycling of cholesterol between the liver and the intestine without having a net effect on fecal neutral sterol excretion. To compensate for increased fecal bile acid loss, also hepatic bile acid synthesis from cholesterol is upregulated. With respect to RCT, less cholesterol originating from macrophages enters the hepatic cholesterol pool, since SR-BI-mediated selective uptake from diabetic HDL is impaired. Thereby a smaller fraction of this cholesterol is then used for bile acid synthesis. These changes are reflected by decreased overall RCT, primarily due to reduced tracer excretion within the fecal bile acid fraction.
In conclusion, insulin-deficient T1DM mice exhibit decreased RCT despite increased biliary sterol secretion. These unfavorable changes are conceivably due to decreased properties of glycated HDL to function in hepatic selective uptake. Impaired RCT is expected to contribute to the increased risk for atherosclerotic CVD morbidity and mortality in patients with T1DM. Feces were collected continuously up to 48 h and were dried, weighed, and thoroughly ground. Aliquots were separated into bile acid and neutral sterol fractions as detailed in materials and methods, and counts recovered from the respective aliquots were related to the total amount of feces produced over the whole experimental period (C). All obtained counts were expressed relative to the administered tracer dose. Data are given as means ± SEM. * P<0.05 compared to PBS-injected control mice. HDL catabolic rate
